Marksans Pharma Limited

Nitin Agarwal

DAM Capital Advisors Ltd

17.7%

cts. A strong revenue growth, and a focus on cost efficiencies, resulted in an improved margins of 17.7% in the quarter. Moving on to the operational environment, it continued to remain tough with high

8 billion

va India, that has a potential to scale up our manufacturing footprints in India, by an additional 8 billion units per annum, over the period of next two years. This will drive our transformational growth jo

500 bps

ption. That will potentially have costsynergies and potential gross and EBITDA margin expansion of 500 bps. Our focus on R&D remains, with a product pipeline being very strong we plan to launch several pr

2.1%

y strong we plan to launch several products with high value in the next two years. R&D expense was 2.1% of the revenue, at Rs. 18.7 crores in H1FY23. We further aim to increase R&D spends, between 4-5%

Rs. 18.7 crore

ch several products with high value in the next two years. R&D expense was 2.1% of the revenue, at Rs. 18.7 crores in H1FY23. We further aim to increase R&D spends, between 4-5% of sales in the coming years. We a

5%

.1% of the revenue, at Rs. 18.7 crores in H1FY23. We further aim to increase R&D spends, between 4-5% of sales in the coming years. We are confident that our market share gains, the volume growth in t

Rs. 452.6 crore

, Sir. I will explain the financial performance of Q2 FY23. For Q2 FY23, our operating revenue was Rs. 452.6 crores, an increase of 25.5% compared with Rs. 361.2 crores last year. US and North America was at Rs. 1

25.5%

al performance of Q2 FY23. For Q2 FY23, our operating revenue was Rs. 452.6 crores, an increase of 25.5% compared with Rs. 361.2 crores last year. US and North America was at Rs. 190.3 crores, representi

Rs. 361.2 crore

FY23. For Q2 FY23, our operating revenue was Rs. 452.6 crores, an increase of 25.5% compared with Rs. 361.2 crores last year. US and North America was at Rs. 190.3 crores, representing a 13.7% increase year-on-ye

Rs. 190.3 crore

crores, an increase of 25.5% compared with Rs. 361.2 crores last year. US and North America was at Rs. 190.3 crores, representing a 13.7% increase year-on-year basis. EU and UK formulation market grew by 32.6% to

13.7%

ared with Rs. 361.2 crores last year. US and North America was at Rs. 190.3 crores, representing a 13.7% increase year-on-year basis. EU and UK formulation market grew by 32.6% to Rs. 193.5 crores. Austr

32.6%

0.3 crores, representing a 13.7% increase year-on-year basis. EU and UK formulation market grew by 32.6% to Rs. 193.5 crores. Australia and New Zealand formulation market recorded 39% growth to INR 43.9